Access Update- #30 I’d like to welcome all of our new Access subscribers. I’m confident that you’ll not only be pleased with your subscription, but also agree that Access is unlike any other newsletter or research service available to individual investors. Our performance so far has been stellar. As of yesterday’s close the portfolio is…
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Email – #440 It’s an overused cliché for sure. But the current market is on track for several of them over the next two months, and they could just determine how the year and many of our positions fare. Storm number 1: The elections. A Democrat win will pinch the financial sector. It’s a dead…
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Access Update- #29 BUY Synta Pharmaceuticals(Nasdaq: SNTA) up to $13.00. Synta Pharmaceuticals’ elesclomol, a novel treatment for late stage melanoma, is currently in phase III trials. There are currently no approved drugs for late stage melanoma, so if elesclomol is approved, SNTA will have the market to itself. If the drug is effective in melanoma,…
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Access Update- #28 A few quick things today: * Electro-Optical Sciences (Nasdaq: MELA) shares are now below our recommended price of $5.75. For those of you who have been patient, waiting for the stock to come in like we said it would – here is your opportunity to buy it. If you do not yet…
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Access Update- #27 Electro-Optical Sciences (Nasdaq: MELA) has been drifting lower in the absence of news.Access subscribers who did not get the chance to buy the stock under our $5.75 limit may have the opportunity to do so in the next few days. The stock is trading just above our limit price, so be ready…
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Email – #439 It’s the last place they leave… and the first place they go back to. I am referring to casinos, specifically MGM Mirage Inc. (NYSE: MGM) a company that I first brought up a couple of months ago, but was reluctant to pull the trigger because I felt it would go lower. I…
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?
Please Log In Type your username and password into the form below. Username Password Log InLost Your Password?